ValuentumAd

Official PayPal Seal













Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
Apr 16, 2024
Johnson & Johnson Narrows 2024 Outlook, Raises Dividend
Image Source: J&J. Looking to 2024, J&J expects adjusted operational sales growth in the range of 5.5%-6%, the midpoint of which is up from the prior range of 5%-6%. Adjusted operational diluted earnings per share is targeted in the range of $10.60-$10.75 per share, the midpoint also up from the range of $10.55-$10.75 previously. Management also upped its dividend 4.2%, to a quarterly payout of $1.24 per share, implying a forward estimated dividend yield of 3.4%. We like J&J, but we won’t be adding it back to any newsletter portfolio anytime soon.
Apr 16, 2024
UnitedHealth Group Reiterates 2024 Adjusted Net Earnings Outlook
Image: UnitedHealth Group’s shares have been choppy during the past couple years. UnitedHealth Group’s shares have seen better days as the firm works to recover from a cyberattack, while the industry’s medical costs are on the rise as patients begin to pursue procedures that were deferred during the peak of the COVID-19 crisis. Though it may be some time for UnitedHealth Group’s performance to normalize given the cyberattack and pent-up demand, we liked that it maintained its adjusted net earnings outlook for 2024 amid concerns of rising costs. UnitedHealth remains a key idea in the Best Ideas Newsletter portfolio.
Apr 15, 2024
Goldman Sachs Delivers in First Quarter
Image Source: Goldman Sachs. Goldman Sachs put up solid first-quarter 2024 results across all lines of its business, revealing that capital markets activity remains very healthy, even in the face of elevated interest rates. Goldman Sachs' book value per share was $321.10 at the end of the first quarter, revealing that shares are trading at 1.25x book at the time of this writing.
Apr 13, 2024
Vertex Pharma to Acquire Alpine Immune Services
Image: Vertex Pharma’s shares have had a nice run the past couple years. On April 10, Vertex Pharma announced that it had entered into an agreement where Vertex will acquire Alpine Immune Services for $65 per share or ~$4.9 billion in cash. We have no qualms with the deal for Alpine, and we expect Vertex Pharma to continue to deliver for shareholders.
Apr 12, 2024
JPMorgan Cautious on Geopolitical Tensions and Inflationary Pressures
Image Source: Hakan Dahlstrom. On April 12, JPMorgan reported mixed first-quarter 2024 results. JPMorgan is one of our favorite banks, in part due to strong leadership at the top and solid fortress-like balance sheet. Though we don’t include any individual bank in the newsletter portfolios, we do think the Financial Select Sector SPDR makes sense for diversification reasons, as showcased in the Best Ideas Newsletter portfolio. Shares of JPMorgan yield ~2.4% at the time of this writing.
Apr 12, 2024
Dividend Increases/Decreases for the Week of April 12
Let's take a look at firms raising/lowering their dividends this week.
Apr 11, 2024
Fastenal Puts Up Mixed First Quarter Results
Image: Fastenal reported mixed first quarter 2024 results. We like its business model quite a bit. On April 11, Fastenal Company reported mixed first-quarter fiscal 2024 results with revenue and earnings per share coming in slightly lower than expectations. Net sales advanced 1.9% for the three-month period ending March 31. The company noted that adverse weather impacted sales in its first quarter by about 10 to 30 basis points on a net basis. Operating income nudged lower in the quarter modestly, while net income advanced 0.9% in the period on a year-over-year basis. Diluted earnings per share was roughly flat in the quarter on a year-over-year basis, increasing 0.6% from the same period a year ago. We like Fastenal’s business model quite a bit, and shares yield ~2.1% at the time of this writing.
Apr 10, 2024
Delta Reports Strong March Quarter; Airline Stocks are Too Risky for Our Taste
Image Source: Colin Brown. Delta’s quarter ending in March was solid, and its full year outlook was encouraging. In general, however, we don’t like airline equities. The extreme ticket price transparency creates an ultra-competitive environment, and overcapacity is always a concern. We view airlines as merely trading vehicles on the health of the global economy and the trajectory of crude oil prices. Delta is operating well, but it will never be able to escape the challenges of its industry, and for those reasons we remain on the sidelines with respect to shares.
Apr 8, 2024
3 Dividend Growth Stocks for the Long Run
Image: Mike Mozart. There are many applications for the discounted cash-flow model. Not only does the tool help to derive a fair value estimate for a company, but the core drivers behind the intrinsic value calculation are also key drivers behind the health of a dividend payer. Stocks with a solid net cash position and also generate strong expected free cash flows more than their cash dividend obligations are in a much better position to grow their payouts in the future than stocks burdened by a net debt position and where their free cash flow comes up short. Apple, Microsoft and Dick’s Sporting Goods make the cut and are three of our favorite dividend growth stocks on the market today.
Apr 8, 2024
What Is Gold Really Worth?
Image: Gold prices have surged since 2020, and they recently hit an all-time high. What is the yellow metal really worth? Let's discuss the greater fool characteristics of the price of gold.


The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.